[go: up one dir, main page]

WO2020045838A1 - Composition de prévention ou de traitement d'une maladie de la prostate, contenant l'extrait de stauntonia hexaphylla et de cornus officinalis comme ingrédients actifs - Google Patents

Composition de prévention ou de traitement d'une maladie de la prostate, contenant l'extrait de stauntonia hexaphylla et de cornus officinalis comme ingrédients actifs Download PDF

Info

Publication number
WO2020045838A1
WO2020045838A1 PCT/KR2019/009518 KR2019009518W WO2020045838A1 WO 2020045838 A1 WO2020045838 A1 WO 2020045838A1 KR 2019009518 W KR2019009518 W KR 2019009518W WO 2020045838 A1 WO2020045838 A1 WO 2020045838A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cornus
prostate disease
honey
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/009518
Other languages
English (en)
Korean (ko)
Inventor
박성선
조경원
정주영
김상민
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Healthcare Corp
Original Assignee
Chong Kun Dang Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Healthcare Corp filed Critical Chong Kun Dang Healthcare Corp
Priority to CN201980055052.XA priority Critical patent/CN112638394A/zh
Publication of WO2020045838A1 publication Critical patent/WO2020045838A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/40—Cornaceae (Dogwood family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition for the prophylaxis or treatment of prostate disease, which contains as an active ingredient extract of Stauntonia hexaphylla and Cornus officinalis Sieb. Et Zucc.
  • the prostate is an accessory gonad consisting of gland tissue and fibromyalgia, which produces and secretes semen.
  • Prostate fluid produced in the prostate gland provides nutrition to the sperm that is made in the testis and moves, and helps the sperm to exercise actively by maintaining the liquid state so that the ejaculated semen does not harden.
  • Representative prostate disorders include enlarged prostate, prostate cancer and prostatitis.
  • Benign prostatic hyperplasia is one of the most common diseases in adult men, with 50% of men over 50 years old and 80% of men over 80 years old reported the highest frequency among male urinary tract disorders. do.
  • the number of patients with prostatic hyperplasia in Korea increased from 45,999 in 2006 to 842,000 in 2011, an increase of 83.5%, and the incidence has increased rapidly in recent years.
  • the size of an adult's prostate is about 20 g, but when the prostate enlarges to an abnormal size and grows to a size of 40 to 400 g, the urinary tract compresses the urinary tract close to the urine more than eight times a day.
  • Bladder storage symptoms such as urinary urinary urges if urinating and urinary feelings are unbearable, delayed urine when urine is used, urinary cessation of interrupted urine flow, or urinary tract discharge. Symptoms of the disorder appear. Patients with prostatic hypertrophy do not need surgical treatment without urinary obstruction or other complications, but about 50% of patients need to be treated until 80 years old.
  • some of the patients with prostatic hyperplasia are associated with prostate cancer, which is not a fatal disease in itself, but it is emerging as an important medical problem in the current society entering the aging society because it lowers the quality of life.
  • Surgical treatment for enlarged prostate was almost performed at the beginning, but since the late 80's, it has been rapidly changed to drug administration.
  • the drugs used in the treatment of conventional prostatic hypertrophy have many side effects and are limited in their efficacy, and thus, it is necessary to develop new therapeutic agents having excellent therapeutic effects without causing side effects or drug resistance.
  • Prostate cancer is the most common cancer among male cancers in the West, and the incidence of prostate cancer is increasing rapidly in Korea.
  • the treatment of prostate cancer differs according to the stage of the disease.
  • Local cancer is treated for the purpose of radical treatment, but metastatic cancer is treated systemically.
  • atmospheric therapy, radical prostatectomy, and radiation therapy may be selected in consideration of the age, health status, sexual function, tumor stage and differentiation, and patient preference.
  • Metastatic prostate cancer can be treated with hormones or with chemotherapy.
  • Prostatitis is an inflammation of the prostate gland and is so common that about 50% of adult men experience symptoms once in their lifetime.
  • Urinary tract infections are most often caused by direct infection of bacteria through the urethra, and can also be caused by disorders of excretion of prostate fluid, urinary tract flow into the prostate, and transmission of inflammation such as hemorrhoids or colitis.
  • prostate diseases such as prostate cancer, enlarged prostate, and prostatitis are associated with androgen
  • a male hormone, anti-androgen drugs that inhibit the expression of androgen receptors can provide treatment and preventive effects or relief of symptoms.
  • prostate specific antigen inhibitors that inhibit the expression of prostate specific antigens are also effective in the prevention and treatment / symptom improvement of the prostate disease affected by prostate specific antigens.
  • 5-alpha reductase inhibitors that inhibit male hormones have been used for the treatment of male diseases caused by male hormones such as prostatic hypertrophy and hair loss.
  • 5-alpha reductase which converts testosterone, a male hormone, to dihydrotestosterone (DHT)
  • DHT dihydrotestosterone
  • 5-alpha reductase has type 1, type 2, and type 3 subtypes.
  • Type 1 is present in various organs such as skin and liver tissue.
  • Type 2 is mainly present in the urinary tract including the liver and prostate.
  • Testosterone is converted to dihydrotestosterone by at least 90% by 5-alpha reductase in prostate tissue and dihydrotestosterone promotes prostate growth with approximately 10 times more activity than testosterone.
  • the efficient inhibition of 5-alpha reductase may reduce the synthesis of physiologically active dihydrotestosterone, which may eventually improve or treat prostatic hyperplasia.
  • the dihydrotestosterone when the dihydrotestosterone is excessively synthesized by 5-alpha reductase, the dihydrotestosterone binds to the androgen receptors around the hair follicles, and the hair follicles shrink and deteriorate, thereby causing hair loss. Therefore, it is possible to efficiently inhibit or treat hair loss by effectively inhibiting 5-alpha reductase.
  • honey can be found in valleys and forests in the southern regions of South Korea such as Jeonnam, Gyeongnam, and Chungnam, and is an evergreen vine plant with creeping vines.
  • the scientific name is Stauntonia Hexaphylla.
  • Stems, leaves, and roots are used as medicinal herbs and are known for their anti-inflammatory, antipyretic, analgesic effects. It can also be used as a cardiac medicine used to return function to normal when the heart is weak or incomplete, or as a diuretic to promote the release of unnecessary water from the body.
  • it is known to be effective in inhibiting subcutaneous fat accumulation, joint diseases, myoma and facial neuralgia.
  • Cornus Fructus is the ripe fruit of Cornus officinalis Siebold et Zuccarini (Horbaceae, Cornaceae), which has been seeded. It is an irregular piece or bag shape, 10-15 mm long, and about 1 cm wide. The outer surface is dark reddish purple to dark purple with shiny and rough wrinkles. The pulp has seed marks, the upper part of the calyx and the lower part of the fruit stalk. The vagina is soft, has a slight smell, tastes sour and slightly sweet. Cornus milk is known to be effective in diuretic, hypotensive, nourishing, anti-allergic, antihistamine, antiacetylcholine, antibarium, and antimicrobial (antifungal).
  • the present inventors have tried to develop a natural product-derived prostate disease treatment agent with no side effects as a result of securing safety, the honey and corn coriander extract has no cytotoxicity, and inhibits the expression of androgen receptor, prostate specific antigen and prostate specific enzyme By confirming the superiority, the present invention was completed by revealing that it can be used as an active ingredient of a composition for preventing or treating prostate disease.
  • An object of the present invention is to provide a composition for the prevention or treatment of prostate disease, containing as an active ingredient extract of Stauntonia hexaphylla and Cornus officinalis Sieb. Et Zucc.
  • Another object of the present invention is to provide a method for preventing or treating prostate disease, comprising administering to a subject a pharmaceutically effective amount of honey extract and cornus extract.
  • Another object of the present invention is to provide a use of the honey extract and cornus extract for use as a composition for the prevention or treatment of prostate disease.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of prostate disease, containing as an active ingredient extract of the honey ( Suntuntonia hexaphylla ) and cornus officinalis Sieb. Et Zucc.
  • the present invention also provides a health food for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.
  • the present invention also provides a food composition for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.
  • the present invention also provides a method of treating prostate disease, comprising administering to a subject a pharmaceutically effective amount of a honey extract and cornus extract.
  • the present invention also provides a method for preventing or ameliorating prostate disease, comprising administering to a subject a pharmaceutically effective amount of a honey extract and cornus extract.
  • the present invention also provides the use of honey extract and cornus extract for use as a pharmaceutical composition for preventing or treating prostate disease.
  • the present invention also provides the use of honey extract and cornus extract for use as a health food for preventing or improving prostate disease.
  • the present invention provides a use of honey extract and cornus extract for use as a food composition for preventing or improving prostate disease.
  • honey and corn coriander extract of the present invention has no cytotoxicity, and has an excellent inhibitory effect on the expression of androgen receptors, prostate specific antigens and prostate specific enzymes, and thus can be used as an active ingredient for preventing or treating prostate disease.
  • honeycomb Suntuntonia hexaphylla
  • Cornus officinalis Sieb. Et Zucc extract or honey and corn cousin extracts prepared in Examples of the present invention in LNCaP cells, respectively 0, 10, 25, 50 ⁇ g / ml After treatment with cytotoxicity is confirmed.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of prostate disease, which comprises as an active ingredient extract of Stauntonia hexaphylla and Cornus officinalis Sieb. Et Zucc.
  • the present invention also provides the use of the honey extract and cornus extract for use as a pharmaceutical composition for the prevention or treatment of prostate disease.
  • honey extract and cornus extract which are the active ingredients of the present invention, is preferably prepared by a method comprising the following steps, but is not limited thereto:
  • the honey or cornus of step 1) can be used without limitation, those grown or commercially available.
  • the honey may be used for flowers, branches, stems, leaves, fruits, ground, root stems, roots, or a combination thereof, and more specifically, honey leaves of honey.
  • the extraction solvent of step 1) is preferably water, alcohol or a mixture thereof.
  • the alcohol C 1 to C 2 lower alcohols are preferably used, and as lower alcohols, ethanol or methanol is preferably used.
  • the extraction method it is preferable to use shaking extraction, Soxhelt extraction or reflux extraction, but is not limited thereto.
  • the extraction solvent is preferably extracted by adding 1 to 20 times the amount of dried honey or cornus oil, more preferably 3 to 17 times, and more preferably 5 to 15 times to extract the extractant. .
  • the extraction temperature is preferably 10 to 100, but is not limited thereto.
  • the extraction time is preferably 1 to 72 hours, but is not limited thereto.
  • the number of extraction is preferably 1 to 5 times, more preferably 3 to 4 repetitions, even more preferably 3 times, but is not limited thereto.
  • the reduced pressure concentration of step 3) is preferably a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the honey extract and cornus extract may be mixed after the preparation of each extract, it is also possible to be prepared in the form of obtaining the extract after mixing the honey and cornus.
  • the composition may contain a honey extract: cornus extract in a weight ratio of 5: 5 to 9.5: 0.5, specifically may be contained in a weight ratio of 6: 4 to 9.5: 0.5, more specifically 7: 3: to 9.5: It may be contained in a weight ratio of 0.5, more specifically may be contained in a weight ratio of 8: 2 to 9.5: 0.5, and more specifically may be contained in a weight ratio of 8.5: 2.5 to 9.5: 0.5.
  • the prostate disease can be, for example, prostate cancer, enlarged prostate or prostatitis.
  • the present inventors prepared honey extract 70% ethanol extract and wild corn 70% ethanol extract, and the extract was mixed in various mixing ratios to prepare a complex honey and cornus extract.
  • the present inventors confirmed the cytotoxicity of the honey and cornus extract in the prostate cancer cells, it was confirmed that the complex extract is not cytotoxic at various concentrations (see Figure 1).
  • the inventors confirmed the protein expression of androgen receptor (AR), prostate specific antigen (PSA) and prostate specific enzyme (5 ⁇ -reductase 2) in prostate cancer cells treated with the honey and cornus complex extract with testosterone, The complex extract was confirmed to have excellent protein, inhibitory effect of AR, PSA and 5 ⁇ -reductase 2 (see Fig. 2).
  • AR androgen receptor
  • PSA prostate specific antigen
  • 5 ⁇ -reductase 2 prostate specific enzyme
  • the present inventors have confirmed that the honey and cornus complex extract of the present invention is not cytotoxic, and the expression inhibitory effect of the androgen receptor, prostate specific antigen and prostate specific enzyme is excellent, the honey and cornus complex extract of the present invention is prostate disease It can be usefully used as a prophylactic or therapeutic pharmaceutical composition, or as an active ingredient of a male composition caused by testosterone, such as a pharmaceutical composition for preventing or treating hair loss.
  • compositions of the present invention may be oral or parenteral (eg, applied or intravenously, subcutaneously, intraperitoneally).
  • Formulations for non-administration may be in the form of powders, granules, tablets, capsules, sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. It may be used in the formulation, and preferably used to prepare an external skin pharmaceutical composition of creams, gels, patches, sprays, ointments, warnings, lotions, linings, pasta or cataplasma. It is not limited to this.
  • Compositions of topical administration may be anhydrous or aqueous, depending on the clinical prescription.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills and the like.
  • Oral liquid preparations include suspensions, solvents, emulsions, syrups, and aerosols.
  • various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • composition may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredient of the present invention for administration.
  • Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added.
  • diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions and the like.
  • compositions are preferably included in an amount of 0.1 to 90 parts by weight based on the composition.
  • Preferred dosages of the compositions of the present invention vary depending on the degree of absorption of the active ingredient in the body, the age, sex and obesity of the patient, but may be appropriately selected by those skilled in the art.
  • oral dosages generally give the adult composition of the present invention per kg of body weight per day to 0.0001 to 500 mg / kg, preferably 0.001 to 300 mg / kg per day, more preferably. Preferably from 0.01 to 200 mg / kg.
  • Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the present invention also provides a health food for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.
  • the present invention also provides a food composition for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.
  • the present invention also provides the use of honey extract and cornus extract for use as a health food for the prevention or improvement of prostate disease.
  • the present invention also provides the use of honey extract and cornus extract for use as a food composition for the prevention or improvement of prostate disease.
  • honey extract and cornus extract, the mixing ratio thereof, prostate disease is the same as the description of the pharmaceutical composition for the prevention or treatment of the prostate disease, the specific description is used for the above, and the following specific to health food or food composition Only the configuration will be described.
  • the honey and corn coriander extract of the present invention has no cytotoxicity, and it was confirmed that the expression inhibitory effect of the androgen receptor, prostate-specific antigen and prostate-specific enzyme, the complex extract of the present invention health for the prevention or improvement of prostate disease It can be usefully used as an active ingredient of a food or food composition.
  • the complex extract of the present invention can be usefully used as an active ingredient of a health food or food composition for preventing or improving hair loss caused by testosterone, such as male disease.
  • the two extracts of the present invention may be provided as a health food or food composition in admixture with a food acceptable carrier.
  • the health food of the present invention includes the form of tablets, capsules, pills or liquids.
  • the two extracts of the present invention When the two extracts of the present invention are used as food or beverage additives, the two extracts may be added as they are or used together with other food or food ingredients, and may be suitably used according to conventional methods.
  • the mixed amount of the two extracts may be suitably determined according to the purpose of use (prevention, health or therapeutic treatment). In the case of long-term intake for health and hygiene or health control, the two extracts can be taken for a long time because there is no problem in terms of safety. There is no particular limitation on the kind of the food.
  • Examples of the food to which the substance may be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, and drinks. Alcoholic beverages and vitamin complexes.
  • the liquid component added in addition to the two extracts when formulated into a beverage is not limited to the above, but may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in conventional beverages.
  • Examples of the aforementioned natural carbohydrates include monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.) and polysaccharides (e.g.
  • the proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 mL of the composition of the present invention.
  • natural flavoring agents taumarin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be used. .
  • the food composition of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (such as cheese, chocolate), pectic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
  • the food composition of the present invention may also contain pulp for the production of fruit and vegetable drinks. These components may be used alone or in combination, and the ratio of such additives is generally selected in the range of 0.001 to 50 parts by weight per total weight of the composition.
  • the present invention also provides a method for preventing or ameliorating prostate disease, comprising administering to a subject a pharmaceutically effective amount of a honey extract and cornus extract.
  • the present invention provides a method of treating prostate disease, comprising administering to a subject a pharmaceutically effective amount of a honey extract and cornus extract.
  • honey extract and cornus extract, the mixing ratio thereof, prostate disease is the same as the description of the pharmaceutical composition for the prevention or treatment of the prostate disease, the specific description uses the above content.
  • the honey and corn coriander extract of the present invention has no cytotoxicity, and it was confirmed that the effect of inhibiting the expression of androgen receptor, prostate specific antigen and prostate specific enzyme, the complex extract of the present invention prevent, improve or treat prostate disease It can be useful for.
  • the complex extract of the present invention can be usefully used for the prevention or improvement of male diseases caused by testosterone, such as hair fall.
  • honey honey extract obtained in ⁇ Example 1> and the cornus extract obtained in the ⁇ Example 2> was mixed in the mixing ratio of the following [Table 1] to prepare a honey extract of the honey and cornus.
  • the survival rate of the prostate cancer cells after treatment with the honey and cornus extract was checked.
  • LNCaP cells (ATCC, USA), a testosterone dependent human prostate cancer cell line, were cultured in 37 ° C. and 5% CO 2 conditions in RPMI-1640 medium (Gibco) containing 10% FBS (fetal bovine serum).
  • the cultured cells were dispensed in 96 well plates at a concentration of 1 ⁇ 10 4 cells / well and incubated for 18 hours under the same conditions.
  • cell viability assay kit EX-cytox; DaeiLab Service, Korea
  • EX-cytox DaeiLab Service, Korea
  • prostate specificity Protein expression of the enzyme (5 ⁇ -reductase 2) was confirmed.
  • LNCaP cells (ATCC, USA) were dispensed in 6 well plates at a concentration of 5 ⁇ 10 4 cells / well and incubated at 37 ° C. for 18 hours.
  • the cultured cells were treated with 1 ⁇ M of testosterone, and at the same time, 25 or 50 ⁇ g / ml of the honey extract prepared in ⁇ Example 1>, 50 ⁇ g / ml of the cornus extract prepared in ⁇ Example 2>, or After treating at a concentration of 50 ⁇ g / ml honey and cornus extract extract prepared in ⁇ Example 3> and further culture for 72 hours and harvested.
  • RIPA buffer 50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate, with a protease inhibitor cocktail. Protein was separated by centrifugation for 20 minutes at a speed of 12,000rpm. The isolated protein was quantified by BCA (Bicinchoninic acid) method.
  • compositions of the present invention are illustrated below.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
  • Foods containing the complex extract of the present invention as an active ingredient were prepared as follows.
  • 0.1 to 5.0 parts by weight of the composite extract of the present invention was added to soups and broth to prepare meat products for health promotion, soups and noodles of noodles.
  • Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
  • Black beans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.
  • the complex extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a sprayer and a hot air dryer was pulverized with a particle size of 60 mesh using a grinder to obtain a dry powder.
  • the grains, seeds and the complex extract of the present invention prepared above were formulated in the following ratio.
  • Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),
  • Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
  • 0.1 g of the complex extract of the present invention was added to 1,000 mL of apple or grape juice to prepare a fruit juice.
  • the nickname relates to a composition for the prevention or treatment of prostate diseases containing the honey extract and cornus extract as an active ingredient, specifically, the honey and cornus extract is not cytotoxic, androgen receptor, prostate specific antigen and prostate specific enzyme Since it is excellent in inhibiting the expression, it can be usefully used as an active ingredient of a composition for preventing or treating prostate disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition de prévention ou de traitement d'une maladie de la prostate contenant, comme ingrédients actifs, des extraits de Stauntonia hexaphylla et de Cornus officinalis. En particulier, les extraits de Stauntonia hexaphylla et Cornus officinalis ne sont pas cytotoxiques et présentent un excellent effet d'inhibition de l'expression des récepteurs d'androgène, des antigènes spécifiques à la prostate et des enzymes spécifiques à la prostate, et ainsi peuvent être utilisés comme ingrédients actifs d'une composition de prévention ou de traitement d'une maladie de la prostate.
PCT/KR2019/009518 2018-08-29 2019-07-31 Composition de prévention ou de traitement d'une maladie de la prostate, contenant l'extrait de stauntonia hexaphylla et de cornus officinalis comme ingrédients actifs Ceased WO2020045838A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980055052.XA CN112638394A (zh) 2018-08-29 2019-07-31 包含日本野木瓜提取物及山茱萸提取物作为有效成分的用于预防或治疗前列腺疾病的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0101933 2018-08-29
KR1020180101933A KR102167290B1 (ko) 2018-08-29 2018-08-29 멀꿀 추출물 및 산수유 추출물을 유효성분으로 함유하는 전립선 질환의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2020045838A1 true WO2020045838A1 (fr) 2020-03-05

Family

ID=69643001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/009518 Ceased WO2020045838A1 (fr) 2018-08-29 2019-07-31 Composition de prévention ou de traitement d'une maladie de la prostate, contenant l'extrait de stauntonia hexaphylla et de cornus officinalis comme ingrédients actifs

Country Status (3)

Country Link
KR (1) KR102167290B1 (fr)
CN (1) CN112638394A (fr)
WO (1) WO2020045838A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119949511B (zh) * 2025-02-10 2025-09-12 山东佰诺生物科技有限公司 一种含有木瓜的药食同源保健品及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150007493A (ko) * 2013-07-11 2015-01-21 상지대학교산학협력단 전립선 비대증 예방 또는 치료용 약학적 조성물 및 이의 제조방법
KR101652073B1 (ko) * 2015-10-12 2016-08-29 충남대학교산학협력단 멀꿀 추출물을 함유하는 전립선 질환의 예방 및 치료용 조성물
KR20160118498A (ko) * 2015-04-02 2016-10-12 유의순 겨우살이, 갈근, 및 산수유 혼합물의 추출물을 유효성분으로 포함하는 항암 조성물
KR20170117339A (ko) * 2016-04-12 2017-10-23 주식회사 케미메디 만성 세균성 전립선염의 예방 또는 치료용 의약 조성물 및 건강기능식품
KR20180084339A (ko) * 2017-01-16 2018-07-25 대구한의대학교산학협력단 혼합 한약재 추출물을 포함하는 탈모방지, 모발흑화, 발모용 및 전립선 비대증 치료용 약학적 조성물 및 그의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102302717B (zh) * 2011-09-30 2012-08-29 姜新田 治疗前列腺疾病的中药组合物、药垫及药垫的制备方法
CN104173681B (zh) * 2014-09-15 2017-05-17 程惠华 一种治疗去势抵抗性前列腺癌的中草药组合物
KR101733477B1 (ko) 2015-06-04 2017-05-11 충남대학교산학협력단 합환피 추출물을 함유하는 전립선 질환의 예방 및 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150007493A (ko) * 2013-07-11 2015-01-21 상지대학교산학협력단 전립선 비대증 예방 또는 치료용 약학적 조성물 및 이의 제조방법
KR20160118498A (ko) * 2015-04-02 2016-10-12 유의순 겨우살이, 갈근, 및 산수유 혼합물의 추출물을 유효성분으로 포함하는 항암 조성물
KR101652073B1 (ko) * 2015-10-12 2016-08-29 충남대학교산학협력단 멀꿀 추출물을 함유하는 전립선 질환의 예방 및 치료용 조성물
KR20170117339A (ko) * 2016-04-12 2017-10-23 주식회사 케미메디 만성 세균성 전립선염의 예방 또는 치료용 의약 조성물 및 건강기능식품
KR20180084339A (ko) * 2017-01-16 2018-07-25 대구한의대학교산학협력단 혼합 한약재 추출물을 포함하는 탈모방지, 모발흑화, 발모용 및 전립선 비대증 치료용 약학적 조성물 및 그의 제조방법

Also Published As

Publication number Publication date
CN112638394A (zh) 2021-04-09
KR20200025093A (ko) 2020-03-10
KR102167290B1 (ko) 2020-10-19

Similar Documents

Publication Publication Date Title
WO2011052846A1 (fr) Composition pharmaceutique contenant des extraits de plantes indigènes comme principes actifs pour prévenir ou traiter le cancer
WO2012033378A2 (fr) Composition comprenant un extrait de cudrania tricuspidata et de coix lachryma-jobi ayant une activité anti-obésité et un effet d'abaissement du taux de sucre dans le sang, et son utilisation
WO2018174589A1 (fr) PROCÉDÉ POUR SOULAGER LA GINGIVITE ET LA PARODONTITE PAR ANTIBIOSE, ANTIOXYDATION, ANTI-INFLAMMATION, SUPPRESSION DE LA PERTE OSSEUSE PARODONTALE ET RÉGÉNÉRATION DE L'OS PARODONTAL AU MOYEN D'UN COMPLEXE D'EXTRAIT DE FEUILLE DE MORINGA OLEIFERA ET D'EXTRAIT D'EUCOMMIA ULMOIDES <i /><i />
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2017116045A1 (fr) Composition destinée à prévenir et traiter un trouble du climatère contenant des extraits de dendropanax morbifera lev. comme principe actif
WO2013141581A1 (fr) Composition pharmaceutique ou aliment naturel comprenant des extraits de fruit de lonicera coerulea var. edulis en tant que principes actifs dans la prévention ou l'amélioration de maladies vasculaires cérébrales ischémiques
WO2015030336A1 (fr) Composition contenant un extrait composite de raisin et de schisandra chinensis pour la prévention ou le traitement de maladies associées au syndrome métabolique
WO2010123221A2 (fr) Composition de prévention et d'amélioration des symptômes de la ménopause contenant des glycéollines comme principe actif
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2020045838A1 (fr) Composition de prévention ou de traitement d'une maladie de la prostate, contenant l'extrait de stauntonia hexaphylla et de cornus officinalis comme ingrédients actifs
KR20180130080A (ko) 자초 추출물을 포함하는 항염용 조성물 및 이의 제조방법
KR20230172783A (ko) 아이소임페라토린을 유효성분으로 포함하는 전립선 관련 질환의 예방 및 치료용 조성물
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2018174424A1 (fr) Composition pharmaceutique pour le traitement prophylactique ou thérapeutique de maladies gynécologiques contenant un extrait de sarcodon imbricatus en tant que principe actif
WO2013069934A1 (fr) Composition pour traiter et prévenir l'obésité, contenant de l'extrait d'agropyre comme principe actif
WO2017146486A1 (fr) Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus
KR20160114841A (ko) 두충피 추출물 또는 이로부터 분리한 아디포넥틴을 유효성분으로 포함하는 비만 개선 또는 치료용 조성물
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2020032296A1 (fr) Composition fonctionnelle
WO2012105816A2 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
WO2015105373A1 (fr) Composition pour la prévention ou le traitement de l'asthme, comprenant un extrait de l'e uonymus alatus ou une fraction de ce dernier
WO2021261707A1 (fr) Composition de soulagement, de traitement, ou de prévention des maladies musculaires, ou d'amélioration des fonctions musculaires, contenant de l'extrait de menthe coréenne ou de la tilianine en tant que principe actif
WO2022270760A1 (fr) Méthode de traitement de la stéatohépatite non alcoolique par la co-administration d'un dérivé de la curcumine et d'un inhibiteur du récepteur de tgf-β
WO2020218840A1 (fr) Composition pour inhiber la perte des cheveux ou favoriser la pousse des cheveux contenant un extrait de plante débarrassé de chlorophylle ou de pigment en tant que principe actif, et son procédé de production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19854350

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19854350

Country of ref document: EP

Kind code of ref document: A1